【摘要】 目的观察格列美脲和格列苯脲治疗2型糖尿病的疗效。方法按标准入选患者共133例,其中格列美脲治疗组81例、格列苯脲组52例。分别给与格列美脲1mg/d,早餐前顿服、格列苯脲1.25mg/d,根据空腹血糖水平,每1～2周调整用药剂量,格列美脲最大剂量为8mg/d、格列苯脲最大剂量为15mg/d。12周后观察患者6项代谢指标的变化。结果两组治疗前后的空腹血糖(FBG)餐后2h血糖(2hBG)及糖化血红蛋白(HbA1c)均明显下降(p<0.05);格列美脲组治疗前后2hC-P明显下降(p<0.05);两组的FC-P及体重指数(BMI)无明显变化。结论格列美脲与格列苯脲的降糖效果相似,但前者可降低餐后C肽水平,是2型糖尿病患者的首选降糖药物。更多还原

【Abstract】 Objective To observe the efficacy of glimepiride and glibenclamide on type 2 diabetes mellitus.Method 133 cases were select by inclusion criteria,and then randomly divided into two groups:glimepiride group(81 cases)and glibenclamide group(52 cases),were given glimepiride 1mg/d、glibenclamide 1.25 mg/d respectively.According to fasting glucose levels,adjustment the dose every 1-2 weeks.The maximum dose:glimepiride is 8 mg/d;glibenclamide is 15 mg/d.After 12 weeks,Observed in patients with metabolic indexes in 6.Result Before and after treatment,there were decreased significantly in two groups with FBG(10.29±2.21 VS 7.21±1.59 mmol/L,p<0.01);2 hBG(14.83±2.68 VS 10.57±1.66 mmol/L,p< 0.01)and HbA1c(9.13±1.37 VS 7.56±1.33 mmol/L,p<0.01);The 2 hC-P of glimepiride group were decreased significantly(2.03±1.21 VS 1.95± 0.92nmol/L,p <0.05);FC-P and BMI had no significant change .Conclusion Glimepiride and glibenclamide had the similar effect of the hypoglycemic,but the former can reduce the postprandial C-peptide levels,is the first choice of hypoglycemic drugs in patients with type 2 diabetes.更多还原